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Summary 
Drug causes of metabolic acidosis are numerous and their mechanisms are diverse. Broadly, they can 
cause metabolic acidosis with either a normal anion gap (e.g. drug-induced renal tubular acidosis) or an 
elevated anion gap (e.g. drug-induced lactic acidosis or pyroglutamic acidosis). This review describes the 
drugs that can cause or contribute to metabolic acidosis during therapeutic use, the mechanisms by 
which this occurs, and how they may be identified in practice. 
  
Introduction 
Acidosis and acidaemia 
Acidosis is a pathological process defined as a tendency to accumulate hydrogen ions (H+) in the body. 
Acidosis may cause acidaemia, which is the accumulation of H+ in blood resulting in a low serum pH 
(conventionally defined as below pH 7.35). The terms are often used interchangeably, although this 
overlooks some important conceptual distinctions: 
1. Whereas acidaemia is always the result of acidosis, not all patients with acidosis have acidaemia. 
This is because the effect of acidosis (the process) on serum pH (the measurable abnormality) 
may be confounded by physiological buffering and compensatory mechanisms, and by co-
existing acid-base disorders. 
2. Whereas acidaemia is measured only in blood, acidosis affects all body compartments, and it 
may not be distributed evenly between them. For example, the acidosis may be more severe 
within cells than in the blood. 
3. Whereas acidaemia is measurable, the presence and severity of acidosis is inferred from the 
clinical context as well as the serum acid-base status. 
Metabolic and respiratory acidosis 
Acidosis and acidaemia are classified as metabolic or respiratory according to the primary disturbance. 
 Metabolic acidosis is due to increased production or reduced excretion of non-volatile acid. 
Metabolic acidaemia is the measurable manifestation of this, defined by a low serum pH and 
low serum bicarbonate concentration ([HCO3-]). However, due to buffering and compensation, 
and in mixed acid-base disturbances, the serum pH may be normal. Metabolic acidosis is then 
inferred from the serum [HCO3-], taking account of the clinical context. For example, the finding 
of a low-normal [HCO3-] in a patient with chronic hypercapnic respiratory failure who usually has 
a high serum [HCO3-] suggests an acute process causing metabolic acidosis. 
 Respiratory acidosis results from insufficient respiratory excretion of volatile acid (carbonic acid, 
as carbon dioxide). The corresponding measurable abnormality in arterial blood is respiratory 
acidaemia, defined by a low serum pH and elevated partial pressure of carbon dioxide (pCO2). 
Serum anion gap in metabolic acidosis 
The anion gap describes the excess of ‘unmeasured anions’ relative to ‘unmeasured cations’ in serum.1 It 
is inferred from the excess of ‘measured cations’ (Na+ and K+) to ‘measured anions’ (HCO3- and Cl-): 
Anion gap = (measured cations) - (measured anions) = ([Na+]+[K+]) - ([HCO3-]+[Cl-]) 
where  [Na+], [K+], [HCO3-], and [Cl-] are the mmol/L concentrations of these ions in serum 
The normal range depends on local reference values of the measured electrolytes, but 10–16 mmol/L is 
typical. In health, the ‘gap’ is explained primarily by albumin, which is negatively-charged at physiological 
pH. Hypoalbuminaemia therefore confounds the interpretation of the anion gap. This may be mitigated 
by applying a correction2: 
Corrected anion gap = AGobs+(0.25×([Alb]norm–[Alb]obs) 
where  AGobs is the observed anion gap in mmol/L 
[Alb]obs is the measured albumin concentration in mg/L 
[Alb]norm is the normal albumin concentration (pragmatically, the midpoint of the 
local reference range, e.g. 44 mg/L)) 
In evaluating a patient with metabolic acidosis, the anion gap may be helpful in delineating, crudely, its 
mechanistic basis: 
 An elevated anion gap suggests accumulation of acid other than hydrogen chloride (HCl). The 
acid dissociates to H+ (which, through buffering, causes [HCO3-] to fall) and a negatively-charged 
conjugate base, for example, lactate or oxalate. The base constitutes an ‘unmeasured anion’, and 
increases the anion gap. 
 A normal anion gap suggests losses of sodium bicarbonate relative to chloride, or a defect in 
renal excretion of HCl. Either way, the result is metabolic acidosis with hyperchloraemia. Since 
the fall in [HCO3-] (either through losses or buffering) occurs in proportion to the rise in [Cl-], the 
anion gap remains normal. 
Drug causes of metabolic acidosis 
This review focuses on drugs that cause or exacerbate metabolic acidosis during therapeutic use (Table 
1), rather than those which cause acidosis only in toxicity. 
Normal anion gap (hyperchloraemic) metabolic acidosis 
Intestinal fluid losses 
The commonest cause of normal anion gap metabolic acidosis is sodium bicarbonate losses from the 
intestinal tract (distal to the stomach). This is usually evident from the clinical context. Where relevant, 
drug causes of diarrhoea, which are numerous, should be considered. 
Renal tubular acidosis 
Renal tubular acidosis (RTA) describes a group of conditions in which there is impairment of urinary HCl 
excretion in the distal tubule (type 1), HCO3- reabsorption in the proximal tubule (type 2), or 
hypoaldosteronism (type 4). All cause metabolic acidosis with a normal anion gap, assuming glomerular 
filtration is normal. Types 1 and 2 RTA usually cause severe acidosis with hypokalaemia, while type 4 RTA 
causes mild acidosis with hyperkalaemia. 
Type 1 (distal) RTA 
The antifungal drug amphotericin has various nephrotoxic effects, including causing dose-related 
impairment of urinary acidification with hypokalaemia.3 This may be due to increased permeability of the 
tubular epithelium, permitting diffusion of ions along their concentration gradients (H+ from filtrate into 
tubular cells; K+ from tubular cells into filtrate).4 Liposomal amphotericin is less toxic to the glomerular 
epithelium than conventional amphotericin. However, the tubular epithelium remains sensitive to high-
dose liposomal amphotericin,5 so acidosis and hypokalaemia can still occur.6 
Lithium, a mood stabilising agent, primarily affects renal concentrating capacity (causing nephrogenic 
diabetes insipidus), but it can also cause mild impairment of tubular acid secretion, giving an incomplete 
type 1 RTA picture.7,8 
Type 2 (proximal) RTA 
Type 2 RTA may occur as part of a syndrome of generalised proximal tubular dysfunction (Fanconi 
syndrome). Functions of the proximal tubule include recovering organic solutes, potassium and 
phosphate from filtrate, and excreting HCl. Accordingly, the features of Fanconi syndrome include 
glycosuria, aminoaciduria, proteinuria, hypokalaemia, hypophosphataemia and hyperchloraemic acidosis. 
Ifosfamide, a cytotoxic alkylating agent, causes dose-related nephrotoxicity through proximal tubular 
injury, resulting in a Fanconi-like syndrome.9 This effect is not shared by its structural relative 
cyclophosphamide. This may be because it is mediated by chloroacetaldehyde, which is a major 
metabolite of ifosfamide but only a minor metabolite of cyclophosphamide.10 Other drug causes of 
Fanconi-like syndromes include the anticonvulsant valproate and the nucleotide reverse transcriptase 
inhibitor tenofovir.11,12 
Acetazolamide, used mainly in glaucoma, causes isolated proximal RTA (i.e. without the other features of 
Fanconi syndrome) through inhibition of carbonic anhydrase. Indeed, on the rare occasions in which it is 
used as a respiratory stimulant, metabolic acidosis is a desired effect. The anticonvulsants topiramate 
and zonisamide can also inhibit carbonic anhydrase and cause isolated proximal RTA.13,14 The risk appears 
not to be predictable from dosage or duration of therapy, and may be related to genetic susceptibility 
factors.13 
Type 4 RTA (hypoaldosteronism) 
Deficiency of aldosterone action, due to absolute or relative aldosterone deficiency, reduces sodium 
reabsorption in the collecting tubules. This lowers the electrochemical gradient that drives K+ and H+ 
excretion. In addition, it probably reduces tubular ammonium production and excretion elsewhere in the 
nephron.14 The overall effect is mild metabolic acidosis with a normal anion gap and hyperkalaemia. 
Drug causes of hypoaldosteronism include the aldosterone antagonists spironolactone and 
eplerenone.15,16 Trimethoprim also has aldosterone-antagonist effects and has been associated with 
hyperkalaemic RTA.17,18 Usually, though not always, this in the context of high-dose treatment with co-
trimoxazole, of which trimethoprim is a constituent. The calcineurin inhibitors ciclosporin and tacrolimus 
can induce aldosterone resistance, resulting in type 4 RTA; they can also cause hypokalaemic (type 1 or 2) 
RTA and other forms of tubular dysfunction.19 
Sodium chloride 
Sodium chloride 0.9% is a widely used intravenous infusion solution. It causes a dose-dependent 
hyperchloraemic metabolic acidosis.20 Hyperchloraemia results from the chloride concentration of the 
solution which, at 154 mmol/L, is substantially higher than that of serum (around 100 mmol/L). Acidosis 
may be due to an unbalanced effect on the CO2/HCO3- buffer system: HCO3- is diluted while PCO2 is 
independently regulated by respiration.21 An alternative explanation is through its effect on the strong 
ion difference (SID).22 The SID is the difference between positively- and negatively-charged fully-
dissociated ions [(Na++ K++Mg++Ca2+)–(Cl-+lactate)]), and is argued to be one of three independent 
variables that determine serum pH (the others being PCO2 and total weak acid concentration).23 
Hyperchloraemia reduces the SID which, to maintain electroneutrality, causes [H+] to increase (so pH 
falls). Whether this mathematical explanation reflects the biochemical mechanisms is debated.21,22 
‘Balanced’ crystalloid solutions, which have an electrolyte composition closer to that of serum (such as 
Hartmann’s solution), cause less metabolic derangement than sodium chloride.20 Metabolism of lactate 
contained in these solutions has an alkalinising effect. 
Elevated anion gap metabolic acidosis 
Renal failure 
Impaired glomerular filtration leads to accumulation of non-volatile acids. These include inorganic acids 
(e.g. sulfuric and phosphoric acids) and non-metabolisable organic acids (uric, pyroglutamic and hippuric 
acids). The result is metabolic acidosis with an elevated anion gap. Nephrotoxic drugs, which are 
numerous, should always be considered as possible causes or contributors to impaired renal function. 
Lactic acidosis 
In anaerobic metabolism, lactate is produced from pyruvate to replete cellular stores of nicotinamide 
adenine dinucleotide (NAD+), which is necessary to sustain continued glycolysis. Subject to sufficient 
oxygen, lactate is subsequently converted back to pyruvate, to be used in oxidative phosphorylation 
(aerobic respiration to generate adenosine triphosphate (ATP)) or gluconeogenesis (which requires ATP). 
The net effect on acid-base balance is neutral, as H+ released during glycolysis is consumed during lactate 
metabolism. However, if oxidative phosphorylation is impaired, as in hypoxia, the unbalanced release of 
H+ from glycolysis and ATP hydrolysis causes acidosis. As this occurs alongside lactate accumulation, the 
resulting syndrome may be termed ‘lactic acidosis’ (defined clinically as acidaemia with a serum lactate 
concentration >5 mmol/L). Mechanistically, however, it should be appreciated that lactate is not itself 
responsible for acidosis.24  
Lactic acidosis associated with global tissue hypoxia (and the resulting shift from aerobic to anaerobic 
respiration) is termed ‘type A’. Drugs that reduce cardiac output or tissue perfusion (e.g. negatively-
inotropic and vasodilatory drugs, such as beta-blockers and nitrates, respectively) may contribute to this, 
although usually in the context of an acute illness or overdose. Lactic acidosis may also arise from 
accelerated aerobic glycolysis (i.e. without global tissue hypoxia; ‘type B’) due to β2-adrenergic 
stimulation.25 β2-agonist drugs, including the bronchodilator salbutamol and the inotrope dopexamine, 
may cause lactic acidosis through this mechanism. 
The nucleoside reverse transcriptase inhibitors stavudine and didanosine,26 and the anti-staphylococcal 
antibiotic linezolid,27 can cause type B lactic acidosis at therapeutic dosages by interfering with 
mitochondrial oxidative phosphorylation. Likewise, the anti-hyperglycaemic agent metformin, widely 
used in type 2 diabetes, acts through inhibition of complex I of the electron transport chain,28 impeding 
oxidative phosphorylation. In toxicity (overdose or reduced renal elimination), this may cause lactic 
acidosis. Whether metformin causes lactic acidosis during therapeutic use in patients with normal renal 
function has been a subject of much debate. Case reports notwithstanding, clinical trial and observational 
data suggest that the risk is not significantly higher than the background rate in patients with diabetes.29 
A rare but serious adverse effect of the anaesthetic agent propofol is a syndrome characterised by 
metabolic acidosis, rhabdomyolysis, renal failure and cardiovascular collapse. This may be mediated by 
mitochondrial toxicity, either through interference with the electron transport chain (at complexes II and 
IV) or fatty-acid oxidation, causing failure of ATP production and metabolic acidosis with 
hyperlactataemia.30 This ‘propofol infusion syndrome’ (PRIS) is probably related to cumulative exposure, 
and it is therefore recommended that the rate of prolonged infusions should not exceed 4 mg/kg/hr.31 
However, PRIS has been reported after short infusions,30 suggesting susceptibility factors in some 
individuals. 
Propylene glycol is used as a solvent in some parenteral drug preparations, notably lorazepam and 
diazepam. High-dose treatment with these agents may cause high anion gap metabolic acidosis 
associated with a high osmolal gap (the difference between measured and calculated serum 
osmolality).32 Metabolism of propylene glycol produces varying amounts of L-lactate (the isomer that 
predominates in mammalian biology, and which measured in most clinical assays) and D-lactate. D-lactic 
acidosis should be suspected in patients with risk factors (including exposure to drugs containing 
propylene glycol as an excipient) and high anion gap acidosis, in whom the anion gap is not explained by 
the measured L-lactate concentration. 
Ketoacidosis 
Ketoacidosis is most commonly seen in states of absolute or near-absolute insulin deficiency (usually, but 
not exclusively, in type 1 diabetes), and in alcohol abuse. Sodium-glucose co-transporter 2 (SGLT-2) 
inhibitors (dapagliflozin, canagliflozin, empagliflozin) have been associated with euglycaemic diabetic 
ketoacidosis.33 The tendency to ketoacidosis is most likely to be related to the underlying insulin 
deficiency state. However, the contribution of SGLT-2 inhibitors complicates the picture, as 
hyperglycaemia (a key diagnostic clue) may be mild or absent due to drug-induced glycosuria. 
Furthermore, the resulting osmotic diuresis may exacerbate hypovolaemia. 
Pyroglutamic acidosis 
Pyroglutamic acidosis arises from disruption of the ATP-dependent γ-glutamyl cycle. The resulting 
accumulation of pyroglutamic acid (5-oxoproline) causes high anion gap metabolic acidosis. Although a 
rare cause of metabolic acidosis, it is important due to its association with two widely used drugs, 
paracetamol and flucloxacillin,34,35 and because it is often unrecognised. Chronic paracetamol therapy 
contributes to the risk of pyroglutamic acidosis through depletion of glutathione stores, while 
flucloxacillin inhibits 5-oxoprolinase, the enzyme responsible for metabolising pyroglutamic acid to 
glutamic acid. 
Pyroglutamic acidosis should be suspected in cases of high anion gap acidosis where the anion gap 
cannot be attributed to lactate or ketone accumulation, particularly if there are other risk factors (e.g. 
malnutrition, paracetamol and flucloxacillin therapy). The diagnosis may be confirmed by urinary organic 
acid measurement, although this is likely to be retrospective. Management is centred on supportive care, 
stopping causative/contributory agents, and replenishing glutathione stores with acetylcysteine.34,35 
Conclusion 
Many drugs can contribute to metabolic acidosis, acting through diverse mechanisms. A careful drug 
history should always form part of the assessment of a patient with metabolic acidosis. This should be 
evaluated alongside the clinical features, serum acid-base status, anion gap (corrected for 
hypoalbuminaemia where applicable) and associated biochemical abnormalities, in order to delineate its 
cause and determine best management. 
  
Clinicopathological 
classification Drug causes Comments 
Normal anion gap   
Intestinal fluid losses  Drug causes of 
diarrhoea 
Intestinal fluid loss (distal to the stomach), including from 
drug-induced diarrhoea, causes sodium bicarbonate losses. 
Type 1 RTA Amphotericin 
 
Associated with hypokalaemia. Amphotericin is also toxic to 
glomerular epithelium, impairing filtration; the liposomal 
formulation is less glomerulotoxic. 
 Lithium Also causes nephrogenic diabetes insipidus. 
Type 2 RTA   
Isolated acidosis and 
hypokalaemia 
Acetazolamide 
Topiramate 
Zonisamide 
Mediated by inhibition of carbonic anhydrase. 
With other features of 
proximal tubular dysfunction 
(Fanconi syndrome) 
Ifosfamide 
Valproate 
Tenofovir 
Associated features may include glycosuria, aminoaciduria, 
proteinuria, hypokalaemia, and hypophosphataemia. 
Type 4 RTA 
(hypoaldosteronism) 
Spironolactone 
Eplerenone 
Trimethoprim 
Ciclosporin 
Tacrolimus 
In type 4 RTA the acidosis is usually mild and associated with 
hyperkalaemia. 
Sodium chloride infusion 0.9% sodium 
chloride 
Dose-related hyperchloraemic acidosis, associated with a 
reduction in the strong ion difference. 
Elevated anion gap   
Nephrotoxicity Nephrotoxic drugs 
(numerous) 
Due to accumulation of various inorganic and non-
metabolisable organic acids. 
Lactic acidosis   
With global tissue hypoxia 
(‘type A’) 
Negatively inotropic 
and vasodilatory 
drugs 
Unlikely as a cause of lactic acidosis during chronic stable 
therapy, but if combined with an acute process (e.g. sepsis), 
drugs that reduce cardiac output (e.g. β-adrenergic blockers) 
may exacerbate tissue hypoxia and worsen lactic acidosis. 
Without global tissue 
hypoxia (‘type B’) 
Salbutamol 
Dopexamine 
Accelerated aerobic glycolysis driven by β2-adrenergic 
stimulation. 
 Stavudine 
Didanosine 
Linezolid 
Interference with mitochondrial function. 
 Propofol Mitochondrial toxicity. Usually, but not exclusively, related to 
extended/high-dose infusion. Other features of the ‘propofol 
infusion syndrome’ include renal failure, cardiovascular 
collapse, rhabdomyolysis and hyperlipidaemia. 
 Metformin A commonly cited example of drug-induced lactic acidosis, but 
metformin probably does not significantly increase the risk at 
therapeutic dosage. 
D-lactic acidosis Lorazepam and 
diazepam (IV 
preparations) 
Caused not by the drug, but the excipient propylene glycol. 
Associated with high osmolal gap. Routine clinical assays may 
not detect D-lactate. 
Euglycaemic diabetic 
ketoacidosis (DKA) 
Dapagliflozin 
Canagliflozin 
Empagliflozin 
DKA is caused by the underlying insulin deficiency state 
(usually type 1 diabetes), but the SGLT-2 inhibitors complicate 
the picture by preventing or minimising hyperglycaemia. 
Pyroglutamic acidosis Paracetamol Depletes glutathione reserves. 
 Flucloxacillin Inhibits 5-oxoprolinase. 
Table 1. Drug causes of metabolic acidosis.  
RTA, renal tubular acidosis; SGLT-2, sodium-glucose co-transporter 2; IV, intravenous.  
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